fbpx

Nyheder

Lundbeckfonden Ventures nyheder

BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the launch of a new corporate web site. The new web site aims to update the BONESUPPORT brand while providing increased educational and clinical CERAMENTT content to an expanding audience. “Our business has...
Funding enables further development of unique metagenomic technology and solutions for gut microbiota-related diseases affecting a large proportion of world populationParis, March 22, 2012 – Enterome, a stratified medicine company developing biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine (metabolic and bowel diseases), today announces a...
  Viaskin Peanut, the first epicutaneous skin patch for the treatment of peanut allergy, is recognized as a unique and promising desensitization product   BAGNEUX, France, February 28, 2012 – DBV Technologies announced today that it has received Fast Track Designation” for the Clinical Development Program of its Viaskin® Peanut, a product designed for the...
  LA JOLLA, Calif., Feb. 15, 2012 /PRNewswire/ — Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has completed a $43 million equity financing to advance its lead investigational product candidate MYDICAR® for the treatment of heart failure. The financing was led...
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced dosing of the first patient in the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) Phase IIIb study of LCP-TacroT in kidney transplant recipients experiencing drug-induced tremors. The STRATO study is designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard...
Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces the initiation of a Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant problem in patients undergoing major surgery, despite the availability of a range of anti-emetic medications. APD421...
  Lund, Sweden; Lloyd Diamond has been recruited CEO of BONESUPPORT – the Swedish medical technology company with a revolutionary orthobiologic platform for treatment of osteoporotic fractures and deep bone infections. Mr. Diamond replaces Dr. Fredrik Lindberg, the co-founder and present CEO, who will remain in the company as Chief Scientific Officer. By the recruitment...
Bagneux, December 6, 2011 – DBV Technologies announces the arrival of David Schilansky – starting December 19 – as Chief Financial Officer and as such, will supervise all financial activities of the company as well as partnerships and Business Development initiatives. David will be a member of the Executive Committee.“The integration of David Schilansky to...
1 60 61 62 63 64

Lundbeckfonden Ventures

Nyheder

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
3. april 2020
Acacia Pharma Group PLC – Publication of Prospectus
25. marts 2020
Acacia Pharma Group PLC – Forthcoming 2020 Annual General Meeting – Change of Venue and Proxy Forms
23. marts 2020